Learn more about emerging treatment options for patients with small cell lung cancer (SCLC) in this engaging, interactive activity. A variety of media (eg, text, video, animation) are used to: provide an overview on SCLC; discuss the rationale for use and the mechanisms of action of checkpoint inhibitors and antibody-drug conjugates (ADCs); and review the latest efficacy and safety data of these agents in SCLC treatment. Expert faculty discuss the potential for these emerging agents in the treatment landscape for this condition.
1.0 AMA PRA Category 1 Credit™
0.7 Contact Hour
Mar 9, 2018
Mar 9, 2019
Leora Horn, MDVanderbilt-Ingram Cancer Center
Nashville, Tennessee, United States
Jonathan Lehman, MD, PhDVanderbilt-Ingram Cancer Center
Nashville, Tennessee, United States
- Epidemiology of SCLC, current medical therapies, and the unmet need for new treatment options
- Rationale for use and mechanisms of action of checkpoint inhibitors and antibody drug conjugates ADCs in SCLC
- Recent clinical trial data examining efficacy and safety of checkpoint inhibitors and ADCs in first-line and recurrent SCLC
- Exploration of how these agents may be incorporated into clinical practice if/when they are approved for use
This educational activity is designed to meet the educational needs of medical oncologists, thoracic surgeons, pulmonologists, registered nurses, nurse practitioners, physician assistants, and other healthcare professionals who treat and manage patients with lung cancer.
After successful completion of this educational activity, participants should be able to:
- Discuss the rationale for and mechanisms of ADCs and immunotherapy in the treatment of SCLC
- Analyze recent efficacy and safety data evaluating the use of ADCs and checkpoint inhibitors in the treatment of SCLC
This educational activity is supported by a grant from AbbVie.
prIME Oncology is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
prIME Oncology designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Continuing Nursing Education
In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and prIME Oncology. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Postgraduate Institute for Medicine (PIM) has established the maximum number of hours awarded for this Continuing Nursing Education activity to be 1 contact hours.
Designated for 0.7 contact hour of pharmacotherapy credit for Advanced Practice Registered Nurses.
To contact Postgraduate Institute for Medicine, visit www.pimed.com.
This activity is provided by prIME Oncology.
Method of Participation
Links to the posttest are available on the video player pages.
In order to receive credit, participants must successfully complete the online posttest with 75% or higher.
Disclosure of Relevant Financial Relationships
prIME Oncology assesses relevant financial relationships with its instructors, planners, managers, and other individuals who are in a position to control the content of CME activities. Any potential conflicts of interest that are identified are thoroughly vetted by prIME Oncology for fairness, balance, and scientific objectivity of data, as well as patient care recommendations. prIME Oncology is committed to providing its learners with high-quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial entity.
The faculty reported the following financial relationships or relationships to products or devices they or their spouses/life partners have with commercial interests related to the content of this CME activity:
Dr Horn has disclosed that she has received consulting fees from AbbVie, AstraZeneca, Bristol-Myers Squibb, and Genentech. She has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in her presentation.
Dr Lehman has disclosed participation as an investigator for a preclinical study at Vanderbilt University Medical Center funded by Ipsen on novel therapeutics in SCLC. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.
The employees/contractors of prIME Oncology have disclosed:
- Ronald Viggiani, MD (medical director content reviewer/planner) – no relevant financial relationships
- Kristin Tomlinson, PhD (scientific content reviewer/planner) – no relevant financial relationships
- Heather Tomlinson, ELS (editorial content reviewer) – no relevant financial relationships
The PIM planners and managers, Trace Hutchison, PharmD; Samantha Mattiucci, PharmD, CHCP; Judi Smelker-Mitchek, MBA, MSN, RN; and Jan Schultz, MSN, RN, CHCP have nothing to disclose.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Disclosure Regarding Unlabeled Use
This activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration or European Medicines Agency. Please refer to the official prescribing information for each product discussed for discussions of approved indications, contraindications, and warnings.